Skip to Main Content

Author Details

Fathi Elloumi
Inc., Frederick National Laboratory for Cancer Research
2007
25
17
PMIDPaper TitleJournal TitlePublished Year
37140427CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations.Cancer Res2023
37858159UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.J Exp Clin Cancer Res2023
37140427CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations.Cancer Res2023
37858159UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.J Exp Clin Cancer Res2023
35158861New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.Cancers (Basel)2022
36325065Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylation.iScience2022
35158861New Insights on the Genetics of Pheochromocytoma and Paraganglioma and Its Clinical Implications.Cancers (Basel)2022
36325065Integrative epigenomic analyses of small cell lung cancer cells demonstrates the clinical translational relevance of gene body methylation.iScience2022
33196823CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.Nucleic Acids Res2021
34045232Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.Mol Cancer Ther2021
33513156Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.PLoS One2021
33196823CellMiner Cross-Database (CellMinerCDB) version 1.2: Exploration of patient-derived cancer cell line pharmacogenomics.Nucleic Acids Res2021
33513156Epigenetic suppression of SLFN11 in germinal center B-cells during B-cell development.PLoS One2021
34045232Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.Mol Cancer Ther2021
32292401<i>TREML4</i> Promotes Inflammatory Programs in Human and Murine Macrophages and Alters Atherosclerosis Lesion Composition in the Apolipoprotein E Deficient Mouse.Front Immunol2020
32292401<i>TREML4</i> Promotes Inflammatory Programs in Human and Murine Macrophages and Alters Atherosclerosis Lesion Composition in the Apolipoprotein E Deficient Mouse.Front Immunol2020
32652468Candidate biomarker assessment for pharmacological response.Transl Oncol2020
33086069SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.Cell Rep2020
33086069SCLC-CellMiner: A Resource for Small Cell Lung Cancer Cell Line Genomics and Pharmacology Based on Genomic Signatures.Cell Rep2020
32652468Candidate biomarker assessment for pharmacological response.Transl Oncol2020
31113817RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.Cancer Res2019
31733513Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines.iScience2019
31113817RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.Cancer Res2019
31733513Quantitative Proteome Landscape of the NCI-60 Cancer Cell Lines.iScience2019
30553813CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.iScience2018
30553813CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.iScience2018
28877474Long Noncoding RNA PURPL Suppresses Basal p53 Levels and Promotes Tumorigenicity in Colorectal Cancer.Cell Rep2017
28877474Long Noncoding RNA PURPL Suppresses Basal p53 Levels and Promotes Tumorigenicity in Colorectal Cancer.Cell Rep2017
29074539NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH<sup>+</sup> Cancer Stem-like Cells.Cancer Res2017
29074539NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH<sup>+</sup> Cancer Stem-like Cells.Cancer Res2017
26844528Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype.Hepatology2016
26844528Oncogenic driver genes and the inflammatory microenvironment dictate liver tumor phenotype.Hepatology2016
23818899Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine.J Oncol2013
23818899Tissue banking, bioinformatics, and electronic medical records: the front-end requirements for personalized medicine.J Oncol2013
22075577Using pathway modules as targets for assay development in xenobiotic screening.Mol Biosyst2012
22075577Using pathway modules as targets for assay development in xenobiotic screening.Mol Biosyst2012
21131600Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers.Mol Cancer Res2011
21131600Interactions with fibroblasts are distinct in Basal-like and luminal breast cancers.Mol Cancer Res2011
21718502Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples.BMC Med Genomics2011
21718502Systematic bias in genomic classification due to contaminating non-neoplastic tissue in breast tumor samples.BMC Med Genomics2011
20676067A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data.Pharmacogenomics J2010
20676074The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.Nat Biotechnol2010
20676067A comparison of batch effect removal methods for enhancement of prediction performance using MAQC-II microarray gene expression data.Pharmacogenomics J2010
20676074The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models.Nat Biotechnol2010
18671997ACToR--Aggregated Computational Toxicology Resource.Toxicol Appl Pharmacol2008
18671997ACToR--Aggregated Computational Toxicology Resource.Toxicol Appl Pharmacol2008
18489778A comparison of machine learning algorithms for chemical toxicity classification using a simulated multi-scale data model.BMC Bioinformatics2008
18489778A comparison of machine learning algorithms for chemical toxicity classification using a simulated multi-scale data model.BMC Bioinformatics2008
17883842SEARCHPATTOOL: a new method for mining the most specific frequent patterns for binding sites with application to prokaryotic DNA sequences.BMC Bioinformatics2007
17883842SEARCHPATTOOL: a new method for mining the most specific frequent patterns for binding sites with application to prokaryotic DNA sequences.BMC Bioinformatics2007
  • 1 - 50 of 50

Recommended Authors

Wail Ba-Alawi
Princess Margaret Cancer Centre, University Health Network, University Ave.
Career Start Year 2013
Number of shared co-authors 0
Matthew Ung
Norris Cotton Cancer Center, Geisel School of Medicine at Dartmouth
Career Start Year 2013
Number of shared co-authors 0
Elana J Fertig
Johns Hopkins University School of Medicine
Career Start Year 2010
Number of shared co-authors 3
Darragh G McArt
Queen's University Belfast
Career Start Year 2009
Number of shared co-authors 0
Stephen R Piccolo
Brigham Young University
Career Start Year 2008
Number of shared co-authors 2
Yang Xie
Quantitative Biomedical Research Center
Career Start Year 2007
Number of shared co-authors 3
James C Costello
University of Colorado Anschutz Medical Campus
Career Start Year 2006
Number of shared co-authors 2
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 2
Chao Cheng
Baylor College of Medicine
Career Start Year 2005
Number of shared co-authors 1
Adam A Margolin
Icahn School of Medicine
Career Start Year 2004
Number of shared co-authors 1
Steffen Durinck
Genentech Inc.
Career Start Year 2004
Number of shared co-authors 1
Benjamin Haibe-Kains
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2004
Number of shared co-authors 13
Gabriela Alexe
Dana-Farber Cancer Institute
Career Start Year 2004
Number of shared co-authors 1
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year 2003
Number of shared co-authors 3
Obi L Griffith
Washington University
Career Start Year 2003
Number of shared co-authors 0
Leslie Cope
Johns Hopkins University School of Medicine
Career Start Year 2003
Number of shared co-authors 2
Michael Slifker
Fox Chase Cancer Center
Career Start Year 2002
Number of shared co-authors 0
Syed Haider
Institute of Cancer Research
Career Start Year 2002
Number of shared co-authors 3
Olivier Elemento
Meyer Cancer Center
Career Start Year 2002
Number of shared co-authors 4
Yidong Chen
The University of Texas Health Science Center at San Antonio
Career Start Year 2001
Number of shared co-authors 2
Lodewyk F A Wessels
University Medical Centre Mannheim, University of Heidelberg
Career Start Year 2000
Number of shared co-authors 2
Joshua M Stuart
University of California at Santa Cruz
Career Start Year 2000
Number of shared co-authors 6
Paul T Spellman
Oregon Health & Science University Hospital.
Career Start Year 1998
Number of shared co-authors 7
Aedin C Culhane
Dana-Farber Cancer Institute & Harvard School of Public Health
Career Start Year 1996
Number of shared co-authors 18
Andrea Califano
Columbia University
Career Start Year 1993
Number of shared co-authors 8
Kevin R Coombes
Medical College of Georgia
Career Start Year 1990
Number of shared co-authors 3
Luigi Marchionni
Weill-Cornell School of Medicine
Career Start Year 1989
Number of shared co-authors 2
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 3
Paul C Boutros
University of California los angeles
Career Start Year 1970
Number of shared co-authors 7
Rainer Spang
University of Regensburg
Career Start Year 1969
Number of shared co-authors 2

Collaborators

Yves Pommier
Center for Cancer Research, National Cancer Institute
Co-authored papers 11
William C Reinhold
Center for Cancer Research, National Cancer Institute
Co-authored papers 8
Sudhir Varma
Center for Cancer Research, National Cancer Institute
Co-authored papers 8
Vinodh N Rajapakse
Co-authored papers 5
Augustin Luna
Harvard Medical School
Co-authored papers 5
Richard S Judson
Co-authored papers 4
Mirit I Aladjem
National Cancer Institute, Center for Cancer Research
Co-authored papers 4
Chris Sander
Broad Institute of MIT and Harvard
Co-authored papers 3
Mathew J Garnett
Wellcome Sanger Institute
Co-authored papers 2
Dalila B Megherbi
Co-authored papers 2
Chen Zhao
Co-authored papers 2
Russell S Thomas
Co-authored papers 2
Damir Herman
Co-authored papers 2
Timothy S Davison
Co-authored papers 2
Kurt W Kohn
Center for Cancer Research, National Cancer Institute
Co-authored papers 2
Melissa A Troester
Co-authored papers 2
Huixiao Hong
Co-authored papers 2
Pierre R Bushel
Co-authored papers 2
Andreas Scherer
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
Co-authored papers 2
Ming Shi
Co-authored papers 2
Hong Fang
National Center for Toxicological Research (NCTR)
Co-authored papers 2
John Zhang
Co-authored papers 2
Joel S Parker
Lineberger Cancer Center, University of North Carolina
Co-authored papers 2
David J Dix
Co-authored papers 2
Tieliu Shi
Co-authored papers 2
Weida Tong
National Center for Toxicological Research
Co-authored papers 2
Yan Li
Co-authored papers 2
Jun Luo
Co-authored papers 2
John D Minna
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 2
Matthew Woods
Co-authored papers 2
Release 1.2